<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月23日（月）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/sponsored/inside-sterile-fill-capacity-crunch" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/sponsored/inside-sterile-fill-capacity-crunch&quot; hreflang=&quot;en&quot;&gt;Inside the sterile fill capacity crunch&lt;/a&gt;</a></h3>
        <p class="summary">GRAM’s CEO on specialization, re-shoring and rising demand in sterile fill manufacturing.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/sponsored/inside-sterile-fill-capacity-crunch" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/sponsored/community-oncologys-expanding-role-cancer-care-grows-more-complex" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/sponsored/community-oncologys-expanding-role-cancer-care-grows-more-complex&quot; hreflang=&quot;en&quot;&gt;Community oncology’s expanding role as cancer care grows more complex&lt;/a&gt;</a></h3>
        <p class="summary">Community oncology is redefining cancer care—advancing innovation, expanding trial access and keeping high-quality treatment close to home.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/sponsored/community-oncologys-expanding-role-cancer-care-grows-more-complex" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo&quot; hreflang=&quot;en&quot;&gt;Obesity Power Rankings: Who will challenge Lilly and Novo?&lt;/a&gt;</a></h3>
        <p class="summary">In what will be the industry’s most competitively contested market, FENIX power ranks the Top 10 obesity players positioned to outperform</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/catalent-cuts-staff-96-another-round-layoffs-maryland" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/catalent-cuts-staff-96-another-round-layoffs-maryland&quot; hreflang=&quot;en&quot;&gt;Catalent cuts staff by 96 in another round of layoffs in Maryland&lt;/a&gt;</a></h3>
        <p class="summary">Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimor…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/catalent-cuts-staff-96-another-round-layoffs-maryland" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/novo-nordisk-nominates-two-new-industry-vets-its-board-latest-addition-recent-shake" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/novo-nordisk-nominates-two-new-industry-vets-its-board-latest-addition-recent-shake&quot; hreflang=&quot;en&quot;&gt;Novo Nordisk nominates 2 industry vets to board in latest leadership shake-up&lt;/a&gt;</a></h3>
        <p class="summary">The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/novo-nordisk-nominates-two-new-industry-vets-its-board-latest-addition-recent-shake" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/supreme-court-steps-trumps-tariffs-thrown-out" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/supreme-court-steps-trumps-tariffs-thrown-out&quot; hreflang=&quot;en&quot;&gt;Supreme Court steps in: Trump&#x27;s emergency tariffs struck down&lt;/a&gt;</a></h3>
        <p class="summary">After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S. import tariffs, a new Supreme Court ruling now waylays the Trump administration&#x27;s t…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/supreme-court-steps-trumps-tariffs-thrown-out" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/gilead-synthetic-lethality-deal-tokyo-biotech-ipo-novos-ozempic-china-sales-dip" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/gilead-synthetic-lethality-deal-tokyo-biotech-ipo-novos-ozempic-china-sales-dip&quot; hreflang=&quot;en&quot;&gt;Fierce Pharma Asia—Gilead&#x27;s synthetic lethality deal; A Tokyo biotech IPO; Novo’s Ozempic China sales dip&lt;/a&gt;</a></h3>
        <p class="summary">Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/gilead-synthetic-lethality-deal-tokyo-biotech-ipo-novos-ozempic-china-sales-dip" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/astrazeneca-fixed-duration-calquence-combo-wins-fda-nod-amid-mounting-cll-rivalry-beone" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/astrazeneca-fixed-duration-calquence-combo-wins-fda-nod-amid-mounting-cll-rivalry-beone&quot; hreflang=&quot;en&quot;&gt;AstraZeneca&#x27;s fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up&lt;/a&gt;</a></h3>
        <p class="summary">AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration re…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/astrazeneca-fixed-duration-calquence-combo-wins-fda-nod-amid-mounting-cll-rivalry-beone" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/amid-eu-generics-woes-roche-looks-divest-its-former-blockbuster-antibiotic" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/amid-eu-generics-woes-roche-looks-divest-its-former-blockbuster-antibiotic&quot; hreflang=&quot;en&quot;&gt;Roche looks to divest its former blockbuster antibiotic amid EU generics woes &lt;/a&gt;</a></h3>
        <p class="summary">After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facilit…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/amid-eu-generics-woes-roche-looks-divest-its-former-blockbuster-antibiotic" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/novartis-plots-159m-sale-india-unit-maintaining-separate-commercial-rd-business-country" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/novartis-plots-159m-sale-india-unit-maintaining-separate-commercial-rd-business-country&quot; hreflang=&quot;en&quot;&gt;Novartis plots sale of India unit while maintaining separate commercial, R&amp;D business in country&lt;/a&gt;</a></h3>
        <p class="summary">Novartis will transfer its 70.68% stake in Novartis India Limited—a Bombay Stock Exchange-listed company that primarily handles older and off-patent drugs in areas like immunology, neuroscience and pa…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/novartis-plots-159m-sale-india-unit-maintaining-separate-commercial-rd-business-country" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>